Logo

Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders

Share this

Takeda Enters into a License Agreement with Selecta to Develop Gene Therapies for the Treatment of Lysosomal Storage Disorders

Shots:

  • Selecta to receive up front and ~$1.124B upon the achievement of development or commercial milestones or Takeda’s election continue its activities at specified development stages. Selecta is also eligible to receive royalties on future commercial sales
  • The collaboration will utilize Selecta’s ImmTOR platform that accelerates transgene expression and addresses AAV vector immunogenicity to deliver transformative therapies for two indications
  • ImmTOR has the potential to amplify the efficacy of biologic therapies- including redosing of gene therapies- restore the body’s natural self-tolerance in autoimmune diseases & can induce tolerance to highly immunogenic proteins

Ref: Selecta | Image: Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions